Melissa Reimers

Medicine & Life Sciences

1. Prostatic Neoplasms 100%
2. Urinary Bladder Neoplasms 80%
3. Castration 65%
4. Residual Neoplasm 44%
5. Cystectomy 31%
6. Neoplasms 28%
7. Immunotherapy 28%
8. Muscles 25%
9. Survival 23%
10. Liquid Biopsy 22%
11. Circulating Tumor DNA 21%
12. pazopanib 20%
13. Mutation 20%
14. Cohort Studies 20%
15. Neoplasm Metastasis 20%
16. Clinical Trials 19%
17. Urine 19%
18. Peritoneal Neoplasms 18%
19. Hospices 17%
20. DNA 17%
21. Radiotherapy 17%
22. Poly(ADP-ribose) Polymerase Inhibitors 16%
23. Prostatectomy 16%
24. Cyclin-Dependent Kinases 16%
25. Drug Therapy 16%
26. Recombinational DNA Repair 15%
27. Otitis Media 15%
28. Time-to-Treatment 15%
29. Chemoradiotherapy 14%
30. Pandemics 14%
31. abiraterone 14%
32. Robotics 14%
33. Pulmonary Tuberculosis 14%
34. Medicare 14%
35. Gonadotropin-Releasing Hormone 14%
36. Zoledronic Acid 13%
37. Odds Ratio 13%
38. Renal Cell Carcinoma 13%
39. Crohn Disease 13%
40. Urinary Bladder 13%
41. Therapeutics 12%
42. Meals 12%
43. Carcinoma 12%
44. Prostate-Specific Antigen 11%
45. Tuberculosis 11%
46. Hepatocellular Carcinoma 11%
47. PROSTVAC 11%
48. Hormone Antagonists 10%
49. Fats 10%
50. Multiple Myeloma 10%